← Back to Search

Monoclonal Antibodies

PF-07257876 for Ovarian Cancer

Phase 1

Waitlist Available

Research Sponsored by Pfizer

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline through up to 2 years

Awards & highlights

Study Summary

This trial is testing a new drug to see if it's safe and if it works against certain types of cancer.

Eligible Conditions

Squamous Cell Carcinoma
Ovarian Cancer
Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline through up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline through up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants with adverse events (AEs)

Number of participants with clinically significant laboratory abnormalities

Number of participants with dose limiting toxicities (DLTs) in Dose Escalation (Part 1)

+1 more

Secondary outcome measures

Duration of response (DOR)

Immunogenicity of PF-07257876

Intratumor PD-L1 expression

+12 more

Trial Design

3Treatment groups

Experimental Treatment

Group I: Dose Expansion (Part 2) - Cohort 2 (SCCHN)Experimental Treatment1 Intervention

Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive PF-07257876 at the recommended dose from Part 1.

Group II: Dose Expansion (Part 2) - Cohort 1 (NSCLC)Experimental Treatment1 Intervention

Participants with non-small cell lung cancer (NSCLC) will receive PF-07257876 at the recommended dose from Part 1.

Group III: Dose Escalation (Part 1)Experimental Treatment1 Intervention

Participants will receive PF-07257876 at escalating dose levels.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

PF-07257876

2021

Completed Phase 1

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor

4,568 Previous Clinical Trials

10,911,857 Total Patients Enrolled

20 Trials studying Ovarian Cancer

2,757 Patients Enrolled for Ovarian Cancer

Pfizer CT.gov Call CenterStudy DirectorPfizer

3,475 Previous Clinical Trials

8,093,025 Total Patients Enrolled

12 Trials studying Ovarian Cancer

2,223 Patients Enrolled for Ovarian Cancer

Media Library

PF-07257876 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04881045 — Phase 1

Ovarian Cancer Research Study Groups: Dose Escalation (Part 1), Dose Expansion (Part 2) - Cohort 2 (SCCHN), Dose Expansion (Part 2) - Cohort 1 (NSCLC)

Ovarian Cancer Clinical Trial 2023: PF-07257876 Highlights & Side Effects. Trial Name: NCT04881045 — Phase 1

PF-07257876 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04881045 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are receiving treatments as part of this clinical experiment?

"Yes, the details on clinicaltrials.gov confirms that this medical trial is actively recruiting patients. This experiment was first posted in August 18th 2021 and has been amended up to September 22nd 2022. 90 participants are needed from a total of 41 sites across North America ."

Answered by AI

What are the principal aims of this clinical experiment?

"This study will track Number of participants with clinically significant laboratory abnormalities as its primary outcome over a Baseline to end-of-Cycle 1 (each cycle is 28 days) time frame. Secondary objectives encompass Duration of Response (DOR), Intratumor T cell levels, and Multiple dose PK parameter: Time to maximal plasma concentration (Tmax,ss). All these are defined in detail on the trial's page."

Answered by AI

Has the medication PF-07257876 been granted a seal of approval by the FDA?

"PF-07257876 has limited data to back up its safety and efficacy, resulting in a score of 1 on our scale. This is expected since the trial is currently at Phase 1."

Answered by AI

Are there still opportunities available for participants in this research?

"Clinicaltrials.gov reveals that this medical study is still seeking participants, having first been listed on August 18th 2021 and most recently revised on September 22nd 2022."

Answered by AI

How many settings are overseeing this experiment?

"This clinical trial is being held in numerous locations, including The Angeles Clinic and Research Institute (Emergency Back-Up Only) located in Santa Monica, Rhode island Hospital situated in Providence, Pennsylvania, UPMC Hillman Cancer Center - Camp Hill based out of Camp Hill Virginia as well as 41 additional centers."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

2021. "Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04881045.